Cynata Therapeutics (ASX:CYP) said an independent data and safety monitoring board completed a planned review of the first group of patients treated in the phase 1/2 NEREID kidney transplant trial, which did not raise safety concerns for its CYP-001 therapy candidate, granting clearance to proceed to the second group, according to a Thursday Australian bourse filing.

The first group of patients in the trial each received a single intravenous infusion of the candidate around six weeks after receiving a kidney transplant, in addition to standard treatment. There were no episodes of kidney transplant rejection in this group.

The trial is evaluating CYP-001 as a potential treatment to reduce reliance on long-term immunosuppressant drugs in kidney transplant recipients. The second group in the trial will involve another three patients, each of whom will receive two infusions of CYP-001, in addition to standard treatment.

The firm's shares jumped 10% in recent trading on Thursday.